AHAnirban Halder

Anirban Halder

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anirban Halder has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • Rituparna Biswas

    Department of Radiation Oncology, Dr. B.R.A. IRCH, All India Institute of Medical Sciences, New Delhi, India

    15 shared publications
  • Rituparna Biswas

    Department of Radiation Oncology, Malda Medical College, Malda, West Bengal, India

    6 shared publications
  • Aloke Ghosh Dastidar

    Department of Radiation Oncology, Institute of Post-Graduate Medical Education and Research, Kolkata, India

    3 shared publications
  • Gk Rath

    Department of Radiation Oncology, Dr. B. R. A. IRCH, All India Institute of Medical Sciences, New Delhi, India

    3 shared publications
  • Kp Haresh

    Department of Radiation Oncology, Dr. B. R. A. IRCH, All India Institute of Medical Sciences, New Delhi, India

    3 shared publications
  • Krishnangshu Bhanja Choudhury

    Department of Radiation Oncology, Malda Medical College, Malda, West Bengal, India

    3 shared publications

Latest Publications

  • A Prospective Single-arm Cohort Study Assessing the Rate of Radical Conversion following Palliative Radiation in Locally Advanced Head and Neck Cancer Cases Deemed Incurable

    by Rituparna Biswas, Krishnangshu Bhanja Choudhury, Arnab Bose, Anirban Halder

    A BSTRACT: Background: Patients with locally advanced head and neck squamous cell carcinoma (LAHNC) who are considered unsuitable for definitive therapy are commonly managed with palliative intent. However, a subset of patients may demonstrate significant tumor regression following short-course palliative radiotherapy (Pal RT), allowing subsequent radical treatment. This study aimed to evaluate the rate of radical conversion following initial Pal RT using 30 Gy in 10 fractions in patients with initially incurable LAHNC. Materials and Methods: This prospective, longitudinal, single-arm cohort study was conducted in a tertiary care teaching hospital in West Bengal, India, between June 2023 and May 2024. Sixty patients with histopathologically confirmed LAHNC deemed unsuitable for radical therapy because of poor performance status, comorbidities, or extensive disease burden were enrolled. All patients received Pal RT to a dose of 30 Gy in 10 fractions over 2 weeks. Treatment response was assessed 2 weeks after completion of Pal RT using RECIST version 1.1 criteria. Patients achieving complete or partial response (PR) underwent radical radiotherapy (Rad RT) to a cumulative dose of 70 Gy. Symptom relief, treatment-related toxicities, and overall survival were analyzed. Results: PR following Pal RT was observed in 43 patients (71.7%), while stable disease and progressive disease were noted in 23.3% and 5% of patients, respectively. No complete response (CR) was observed after Pal RT. All patients achieving PR subsequently underwent radical conversion. Following Rad RT, CR was achieved in 48.8% of patients and PR in 41.9%, with no cases of progressive disease. Significant symptom palliation was observed, particularly for bleeding (92.3%), pain (70.2%), and dysphagia (60%). No treatment-related mortality occurred. Acute toxicities following Pal RT were predominantly Grade 1 dermatitis and mucositis, while expected Grade 2–3 toxicities were observed after radical treatment. Median overall survival was 8 months in the Pal RT-only group, whereas median survival was not reached in the Rad RT group. Kaplan–Meier analysis demonstrated significantly improved survival among patients undergoing radical conversion (log-rank P < 0.001). Conclusion: Hypofractionated Pal RT with 30 Gy in 10 fractions is an effective and feasible strategy for patients with initially incurable LAHNC. In addition to providing meaningful symptom palliation, this response-adaptive approach identifies favorable responders who may benefit from subsequent radical treatment, resulting in improved survival outcomes.

  • Real-world Effectiveness of Topical Diclofenac in Preventing Capecitabine-induced Hand–Foot Syndrome: A Retrospective Cohort Study

    by Rituparna Biswas, Krishnangshu Bhanja Choudhury, Santu Kumar Chejara, Arnab Bose, Anirban Halder

    A BSTRACT: Background: Capecitabine is widely used in the treatment of various solid tumors but is frequently associated with hand–foot syndrome (HFS), a common and often dose-limiting dermatologic toxicity. The D-TORCH trial recently demonstrated that topical diclofenac significantly reduces the incidence of capecitabine-induced HFS. This study evaluates topical diclofenac for preventing HFS in patients on capecitabine. Materials and Methods: We conducted a retrospective, single-arm, cohort study at a medical college in West Bengal between April 2024 and January 2025. Fifty-two patients with gastrointestinal, hepato-pancreatic-biliary, breast, or skin cancers receiving capecitabine-based regimens and compliant with prophylactic topical diclofenac therapy were included. Patients applied 1% diclofenac gel to their hands twice daily for 12 weeks or until the development of Grade ≥2 HFS. HFS grading was assessed at each chemotherapy cycle per standard clinical protocols. Results: Among 52 eligible patients, 47 (90.4%) completed 12 weeks of chemotherapy without developing clinically significant (Grade ≥2) HFS. Five patients developed Grade ≥2 HFS, all on triplet chemotherapy. One patient (1.9%) developed Grade 3 HFS, which was managed with dose modification. Among 47 patients, mild HFS (Grade 1) was observed in 22 patients (46.8%), while 17 (36.1%) did not develop any HFS. HFS was less frequent and severe with capecitabine monotherapy or doublets than with triplets. Conclusion: Topical diclofenac is a safe, effective, and affordable option for preventing capecitabine-induced HFS, particularly with monotherapy or doublet regimens, supporting its use in routine practice and resource-limited settings.

  • Open Access

    Capecitabine-based triplet (TPX) as induction chemotherapy in advanced head and neck cancer: a daycare-based cohort study

    by Rituparna Biswas Krishnangshu Bhanja Choudhury, Anirban Halder

    Head and neck squamous cell carcinoma (HNSCC) remains a global health burden. Induction chemotherapy using the regimen docetaxel, cisplatin and 5-fluorouracil (TPF) improves outcomes in advanced cases but requires continuous 5-FU infusion, limiting feasibility in daycare settings. Capecitabine, an oral prodrug of 5-FU, offers a convenient alternative. This study evaluates the efficacy and tolerability of a capecitabine-based triplet regimen docetaxel, carboplatin, capecitabine (TPX) as induction chemotherapy in a resource-limited, outpatient setting. This retrospective cohort study included 52 patients with stage IVA–IVB HNSCC treated between August 2023 and March 2025 at a Medical college in West Bengal, India. Patients were intended to receive four cycles of TPX every 21 days. Tumour response was assessed using Response Evaluation Criteria in Solid Tumours, version 1.1 after induction and following definitive therapy (surgery or chemoradiotherapy (CTRT)). Toxicities were recorded per Common Terminology Criteria for Adverse Events, version 5.0. Primary outcomes were response rates and toxicity; secondary outcome was feasibility of proceeding to curative treatment. The cohort (median age 46 years; 65.4% male) had 38.5% oral cavity tumours. Following induction chemotherapy, the overall response rate (ORR) was 84.6%, with 100% ORR after definitive treatment. Oral cavity tumours showed 80% partial response (PR) post-induction; ten patients underwent successful surgery, while others received CTRT. In non-oral cavity cancers, 75% had a PR and 12.5% achieved a complete response post-induction. Toxicity was manageable; grade 3/4 neutropenia occurred in 9.6%, high-grade non-hematologic toxicity was also meagre and no treatment-related deaths were reported. Most patients (76.9%) completed all four cycles. The TPX regimen is a well-tolerated and effective alternative to TPF for induction chemotherapy in advanced HNSCC, especially in daycare settings. It enables high response rates and facilitates curative treatment while avoiding the logistical challenges of infusional 5-FU. Further prospective studies are warranted to confirm survival benefits and support broader adoption.

  • Open Access

    Low-dose olanzapine for cancer-associated anorexia and nausea: insights from clinical practice

    by Rituparna Biswas, Krishnangshu Bhanja Choudhury, Anirban Halder

    Low-dose olanzapine for cancer-associated anorexia and nausea: insights from clinical practice Rituparna Biswas1,a, Krishnangshu Bhanja Choudhury1,b and An


  • Abscopal effect of radiation in metastatic esophageal carcinoma: fourth reported case

    by Rituparna Biswas, Rajesh Jindel, Anirban Halder, Koushik Sen, Apurba Kabasi

    Abscopal or bystander effect of radiotherapy is a rare and unpredictable outcome encountered during treatment of metastatic cancer where tumor regression is observed distant from irradiated volume. While it has been more frequently reported with malignancies like melanoma, lymphoma, and renal cell carcinoma, data regarding metastatic esophageal cancers are sparse. We describe a case of abscopal regression of distant mediastinal and upper abdominal lymph nodes in a 65-year-old gentleman whose primary esophageal tumor was irradiated with hypo-fractionated radiotherapy in an attempt to achieve local palliation. Our case study emphasizes the systemic benefit of local radiotherapy and the need for future research to investigate its utility as this clinical event poses widespread response in an otherwise dismal Stage-IV cancer with minimal treatment-related side effects.


  • Was it Ewing’s? A Diagnostic and Therapeutic Dilemma

    by Anirban Halder, Rituparna Biswas, Mimi Gangopadhyay, Dipanwita Biswas, Rajni Parmar

    We present an atypical case of histopathology suggesting hemangioendothelioma and immunohistochemistry-proven Ewing’s sarcoma in a 39-year-old lady who presented with multiple stony hard swellings involving the occipital region of the scalp, right cervical lymph node, right scapular region, left infraclavicular region of the chest, right anterior abdominal wall swelling, and inner aspect of right thigh. She underwent left-sided below-knee amputation for parosteal osteosarcoma in the left distal tibia 3 years back. Palliative radiotherapy with dose of 30 Gy in 10 fractions over 2 weeks was administered to the right neck and right upper back following which she attained moderate pain relief but no reduction in swellings as was expected had it been a case of hemangioendothelioma or Ewing's sarcoma..

  • Open Access

    Inflammatory myofibroblastic tumor of maxillary sinus successfully treated with radiotherapy and corticosteroid: report of a rare case

    by Rituparna Biswas, Anirban Halder, Mimi Gangopadhyay, Dipanwita Biswas

    Background: Inflammatory myofibroblastic tumor (IMT) is a mesenchymal tumor mainly found in lung or retroperitoneum and rarely affects head and neck region. Extensive English literature search reveals that less than fifty cases of head and neck IMT have been reported so far, maxillary sinus being fewer. Case presentation: We present a case of IMT involving maxillary sinus in a 48-year-old gentleman who attained complete clinico-radiologic response after treatment with radiotherapy (RT) and concurrent oral prednisolone. Conclusions: This is the first report where such magnificent response was attained in primary setting treated with RT and steroids as opposed to surgery which used to be considered as standard of care till now.


  • Treatment Outcome and Patterns of Failure in Patients with Maxillary Sinus Cancer: Clinical Experience from a Regional Cancer Centre in North India

    by Suman Bhasker, Rituparna Biswas, Alok Thakar, Subhash Chander, Ahitagni Biswas, Atul Sharma, Anirban Halder, Srikanth Anne, Bidhu K Mohanti

    Treatment of maxillary sinus cancer poses several challenges because of its complex anatomy, close proximity to critical structures and majority of patients presenting at an advanced stage. Despite presence of several treatment approaches, the outcome in these cancers has remained dismal. This article examines its clinical behaviour and treatment outcome of these patients treated at our centre in past 7 years. In this retrospective study, 67 patients with carcinoma of maxillary sinus presented from January 2011 to December 2017 were analysed. All the patients reporting during this period were included except those who did not turn up after first visit. Of all the patients, 64.2% had squamous cell carcinoma. The majority of patients presented with advanced stage (IVA and IVB, 83.58%). Nodal disease at presentation was seen in seven patients (10.4%). Treatment to the primary site comprised of surgery and radiotherapy in 24 patients, radiotherapy alone in 22 patients and surgery alone in 12 patients. Statistical program for social sciences (SPSS) version 16 was used for all statistical analyses. The mean follow-up time was 25 months (range 3–72 months). Overall, 17 out of 41 patients who were treated with curative intent (41.5%) developed recurrence. Patients who underwent surgery followed by adjuvant radiotherapy did fairly better in terms of recurrence. Seven patients out of 17 (41.2%) could be salvaged by surgery or radiation. Only one patient developed distant metastasis to D8 vertebra. Patients who were treated with surgery and radiotherapy (either preoperative/adjuvant setting) had better disease-free survival. The results of the current study regarding the treatment of carcinoma of the maxillary sinus show feasibility and efficacy of multimodal therapy. Radical radiotherapy appears to be a feasible alternative in cases of inoperable tumours. Loco regional relapse remains a significant pattern of failure.


  • Open Access

    Papillary Tumor of the Pineal Region in an Adolescent

    by Rituparna Biswas, Kalpana Kumari, K P Haresh, Subhash Gupta, Anirban Halder, G K Rath

    Sir, Primary papillary tumors of the central nervous system and particularly the pineal region are rare. Papillary tumor of the pineal region (PTPR) was initially described by Jouvet et al. in 2003.[1] This entity was introduced in the World Health Organization (WHO) classification of brain tumors in 2007, following which it is being diagnosed more frequently.[2] Less than hundred cases of PTPR have been reported in the literature so far.[3] The natural history of this tumor is not well understood due to the limited information and its rarity. Here, we present a case of PTPR in a 15-year-old adolescent. A 15-year-old girl, with no comorbidities, had complaints of headache, nausea, vomiting, and progressive loss of vision in both eyes for 8 months. Clinical examination revealed bilateral upgaze paresis, bilateral papilledema, and bilateral visual acuity of 6/24. Systemic examination was noncontributory. Contrast-enhanced magnetic resonance imaging revealed an enhancing soft-tissue mass (1.9 cm × 2.1 cm × 2.5 cm) in posterior aspect of the third ventricle extending into the cerebral aqueduct bulging into the roof of the fourth ventricle leading to obstructive hydrocephalus [Figure 1]. Then, she underwent near total excision of mass with placement of ventriculoperitoneal shunt. Histopathology suggested papillary tumor of the pineal region (the WHO Grade II/III) [Figure 2]. Tumor cells were immunopositive for chromogranin (diffuse), focally for synaptophysin, and showed faint immunoreactivity for cytokeratin while negative for epithelial membrane antigen (EMA), glial fibrillary acidic protein, and neurofilament. MIB-1 labeling index was low [Figure 3]. She was then administered adjuvant radiation dose of 50.4 Gy in 28 fractions over 5 weeks and 3 days to residual tumor. PTPR is a rare tumor with limited available information on it. As its name implies, PTPR does not arise from the pineal gland itself. The cell of origin is thought to be the specialized ependymocytes of the subcommissural organ.[4] The evolution in the classification of pineal tumors has led to the emergence of PTPR. Based on a series of six tumors with identical histological features, PTPR was first described as a distinct entity in 2003.[1] The WHO 2007 definition of PTPR is as follows: -”A rare neuroepithelial tumor of the pineal region in adults, characterized by papillary architecture and epithelial cytology, immunopositivity for cytokeratin, and ultrastructural features suggesting ependymal differentiation.”[2] To date, there are <100 cases reported in the literature.[3] PTPR generally presents with symptoms of obstructive hydrocephalus secondary to compression of cerebral aqueduct such as headache, vomiting, and visual disturbances.[1] Similarly, in this case, she presented with features of raised intracranial tension. No specific imaging features are pathognomonic for PTPR. However, intrinsic T1 hyperintensity has been reported as a potentially characteristic feature of this neoplasm.[5] The subcommissural organ is involved in the secretion of glycopeptides and is located below the posterior commissure at the level of the cerebral aqueduct, just anterior to the pineal gland. It is the glycopeptide content that is thought to be the source of intrinsic T1 hyperintensity commonly reported in PTPR.[5] Neuroimaging usually displays a large (2–4 cm), well-circumscribed contrast-enhancing tumor, which occasionally has cystic elements.[4] The limited MR imaging reports of PTPRs in the literature have described a heterogeneously enhancing mass in the pineal region.[1] The present case shows similar features to cases in the literature. Histopathologically, PTPR is characterized by an epithelial-like growth pattern in which the vessels are covered with multiple layers of tumor cells forming perivascular pseudorosettes, similar to our case.[6] Immunoreactivity for cytokeratin in the papillary structures is most distinctive feature and absent dot-like EMA staining in these tumors rules out ependymomas. Faint and focal reactivity for neuroendocrine markers are described, however, in the present case, we found diffuse immunoreactivity for chromogranin and focally for synaptophysin.[7] The prognosis of PTPR is uncertain. These tumors are characterized by frequent local recurrence, and thus, the literature currently suggests they may be graded either II or III but complete criteria for grading are not yet formulated.[7] In a series of 31 cases reviewed by Fèvre-Montange et al., progression was identified in 72% of cases, with 5-year estimates of overall and progression-free survival set at 73% and 27%, respectively. Incomplete resection and a mitotic index higher than five per 10 high-power fields were correlated with decreased survival and increased recurrence. Gross total resection was the only clinical factor strongly associated with overall survival and recurrence, but the results were not statistically significant.[8] Due to the few reported cases of PTPR, there are no current standard treatment options beyond gross total resection, although complete resection is not possible in most of the times, hence, surgical resection followed by radiotherapy is the preferred treatment.[9] Although PTPR is a rare tumor, it is being recognized more commonly nowadays due to the awareness of neuropathologists and should be considered in the differential diagnoses of tumors of the pineal region. More studies with larger patient population are required to determine the prognosis and standard treatment protocol of this rare entity. As of now, maximal safe resection followed by adjuvant radiation should be considered owing to high recurrence rate. The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand...


  • Open Access

    Triple horror: A rare case of triple metachronous malignancy

    by Subhash Gupta, Rituparna Biswas, Kp Haresh, Sandeep Mathur, Anirban Halder, Gk Rath

    Lung India, Official publication of the Indian Chest Society